Walter M. Stadler to Risk Assessment
This is a "connection" page, showing publications Walter M. Stadler has written about Risk Assessment.
Connection Strength
0.327
-
Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis. Urology. 2004 Nov; 64(5):976-81.
Score: 0.147
-
Prognosis and prediction in a Facebook world. Cancer. 2009 Dec 01; 115(23):5368-70.
Score: 0.052
-
Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 01; 27(22):3573-4.
Score: 0.051
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
Score: 0.020
-
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 01; 30(13):1534-40.
Score: 0.015
-
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011 Apr 20; 29(12):1525-30.
Score: 0.014
-
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6.
Score: 0.012
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18.
Score: 0.009
-
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
Score: 0.006